Preclinical shock strategies to reactivate latent HIV-1: An update

HIV-1 latency; DNA methylation; Human immunodeficiency virus 1; Human immunodeficiency virus 1 infection; Review; T lymphocyte activation; T wave; HIV Infections; Antiviral Agents; Drug Therapy, Combination; HIV-1; Humans; Transcription, Genetic; Virus Activation; Virus Latency

Abstract :

[en] Purpose of review The 'shock and kill' strategy consists of activating HIV-1 expression to allow latently infected cells to die from viral cytopathic effects or host cytolytic immune effectors. This strategy relies on small molecules, called latency reversing agents, which activate HIV transcription. Recent findings Several mechanisms operating at the transcriptional level are involved in the establishment and maintenance of HIV-1 latency, including the absence of crucial inducible host transcription factors, epigenetic silencing, and the sequestration of the positive transcription elongation factor B. Progresses made toward the understanding of the molecular mechanisms of HIV-1 transcriptional repression have led to the identification of latency reversing agents that activate HIV transcription, such as histone deacetylase inhibitors or protein kinase C agonists. Multiple studies have recently pointed interesting ways to optimize the shock strategy by using combinations of latency reversing agents with an appropriate time schedule. Summary Combining latency reversing agents appears as one potential strategy for therapy against HIV-1 latency. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

Disciplines :

Immunology & infectious disease

Author, co-author :

DARCIS, Gilles ; Centre Hospitalier Universitaire de Liège - CHU > Service des maladies infectieuses - médecine interne

Van Driessche, B.; Service of Molecular Virology, Département de Biologie Moléculaire (DBM), UniversitéLibre de Bruxelles (ULB), Rue des Professeurs Jeener et Brachet 12, Gosselies, Belgium

Van Lint, C.; Service of Molecular Virology, Département de Biologie Moléculaire (DBM), UniversitéLibre de Bruxelles (ULB), Rue des Professeurs Jeener et Brachet 12, Gosselies, Belgium

Language :

English

Title :

Preclinical shock strategies to reactivate latent HIV-1: An update

Publication date :

2016

Journal title :

Current Opinion in HIV and AIDS

ISSN :

1746-630X

Publisher :

Lippincott Williams and Wilkins

Volume :

Issue :

Pages :

388-393

Peer reviewed :

Peer reviewed

Available on ORBi :

since 17 January 2018

Statistics

Number of views

35 (3 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Deeks SG. HIV: shock and kill. Nature 2012; 487:439-440.
Van Lint C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. Retrovirology 2013; 10:67.
Saayman S, Roberts TC, Morris KV, Weinberg MS. HIV latency and the noncoding RNA therapeutic landscape. Adv Exp Med Biol 2015; 848:169-189.
Cary DC, Fujinaga K, Peterlin BM. Molecular mechanisms of HIV latency. J Clin Invest 2016; 126:448-454.
Mbonye U, Karn J. Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology 2014; 454-455; 328-39.
Yang G, Thompson MA, Brandt SJ, Hiebert SW. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Oncogene 2007; 26:91-101.
Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 2009; 6:111.
Archin NM, Espeseth A, Parker D, et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25:207-212.
Matalon S, Palmer BE, Nold MF, et al. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4+ T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr 2010; 54:1-9.
Contreras X, Schweneker M, Chen CS, et al. Suberoylanilide hydroxamic acid reactivates HIVfromlatently infected cells. J BiolChem2009;284:6782-6789.
Reuse S, Calao M, Kabeya K, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 2009; 4:e6093.
Quivy V, Adam E, Collette Y, et al. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J Virol 2002; 76:11091-11103.
Mates JM, de Silva S, Lustberg M, et al. A novel histone deacetylase inhibitor, AR-42, reactivates HIV-1 from chronically and latently infected CD4 T-cells. Retrovirology (Auckl) 2015; 7:1-5.
Wei DG, Chiang V, Fyne E, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 2014; 10:e1004071.
Bouchat S, Delacourt N, Kula A, et al. Sequential treatment with 5-aza-2'- deoxycytidine and deacetylase inhibitors reactivates HIV-1. EMBO Mol Med 2015; 8:117-138
Bullen CK, Laird GM, Durand CM, et al. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 2014; 20:425-429.
Cillo AR, Sobolewski MD, Bosch RJ, et al. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2014; 111:7078-7083.
Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM. Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J Biol Chem 2013; 288:14400-14407.
Jamaluddin MS, Hu PW, Jan Y, et al. Short communication: the broadspectrum histone deacetylase inhibitors vorinostat and panobinostat activate latent HIV in CD4+ T cells in part through phosphorylation of the T-loop of the CDK9 subunit of P-TEFb. AIDS Res Hum Retroviruses 2016; 32:169-173.
Marban C, Suzanne S, Dequiedt F, et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J 2007; 26:412-423.
Bouchat S, Gatot JS, Kabeya K, et al. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAARTtreated patients. AIDS 2012; 26:1473-1482.
Imai K, Togami H, Okamoto T. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem 2010; 285:16538-16545.
Bernhard W, Barreto K, Saunders A, et al. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett 2011; 585:3549-3554.
Kauder SE, Bosque A, Lindqvist A, et al. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009; 5:e1000495.
Blazkova J, Trejbalova K, Gondois-Rey F, et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 2009; 5:e1000554.
Blazkova J, Murray D, Justement JS, et al. Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy. J Virol 2012; 86:5390-5392.
Palacios JA, Perez-Pinar T, Toro C, et al. Long-term nonprogressor and elite controller patients who control viremia have a higher percentage of methylation in their HIV-1 proviral promoters than aviremic patients receiving highly active antiretroviral therapy. J Virol 2012; 86:13081-13084.
Fujinaga K, Luo Z, Schaufele F, Peterlin BM. Visualization of positive transcription elongation factor b (P-TEFb) activation in living cells. J Biol Chem 2015; 290:1829-1836
Trushin SA, Bren GD, Asin S, et al. Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta. J Virol 2005; 79:9821-9830.
Fujinaga K, Barboric M, Li Q, et al. PKC phosphorylates HEXIM1 and regulates P-TEFb activity. Nucleic Acids Res 2012; 40:9160-9170.
Sung TL, Rice AP. Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells. Retrovirology 2006; 3:66.
Pandelo Jose D, Bartholomeeusen K, da Cunha RD, et al. Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology 2014; 462-463; 328-39.
Barboric M, Nissen RM, Kanazawa S, et al. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell 2001; 8:327-337.
Mehla R, Bivalkar-Mehla S, Zhang R, et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PloS One 2010; 5:e11160.
Darcis G, Kula A, Bouchat S, et al. An in-depth comparison of latencyreversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatin-1+JQ1 and ingenol-B+JQ1 to potently reactivate viral gene expression. PLoS Pathog 2015; 11:e1005063.
Diaz L, Martinez-Bonet M, Sanchez J, et al. Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-kB-dependent mechanism. Sci Rep 2015; 5:12442.
Bocklandt S, Blumberg PM, Hamer DH. Activation of latent HIV-1 expression by the potent antitumor promoter 12-deoxyphorbol 13-phenylacetate. Antiviral Res 2003; 59:89-98.
Biancotto A, Grivel JC, Gondois-Rey F, et al. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 2004; 78:10507-10515.
Kulkosky J, Culnan DM, Roman J, et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001; 98:3006-3015.
Korin YD, Brooks DG, Brown S, et al. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol 2002; 76:8118-8123.
Williams SA, Chen LF, Kwon H, et al. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 2004; 279:42008-42017.
Abreu CM, Price SL, Shirk EN, et al. Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PloS One 2014; 9:e97257.
Jiang G, Mendes EA, Kaiser P, et al. Reactivation of HIV latency by a newly modified ingenol derivative via protein kinase Cdelta-NF-kappaB signaling. AIDS 2014; 28:1555-1566.
Jiang G, Mendes EA, Kaiser P, et al. Synergistic reactivation of latent HIV expression by ingenol-3-angelate, PEP005, targeted NF-kB signaling in combination with JQ1 induced p-TEFb activation. PLoS Pathog 2015; 11:e1005066
Jiang G, Dandekar S. Targeting NF-kappaB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. AIDS Res Hum Retroviruses 2015; 31:4-12.
Peterlin BM, Price DH. Controlling the elongation phase of transcription with P-TEFb. Mol Cell 2006; 23:297-305.
Budhiraja S, Famiglietti M, Bosque A, et al. Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells. J Virol 2013; 87:1211-1220.
Chiang K, Rice AP. MicroRNA-mediated restriction of HIV-1 in resting CD4+ T cells and monocytes. Viruses 2012; 4:1390-1409.
Chiang K, Sung TL, Rice AP. Regulation of cyclin T1 and HIV-1 Replication by microRNAs in resting CD4+ T lymphocytes. J Virol 2012; 86:3244-3252.
Hoque M, Shamanna RA, Guan D, et al. HIV-1 replication and latency are regulated by translational control of cyclin T1. J Mol Biol 2011; 410:917-932.
Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem 2012; 287:36609-36616.
Banerjee C, Archin N, Michaels D, et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 2012; 92:1147-1154.
Boehm D, Calvanese V, Dar RD, et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 2013; 12:452-462.
Zhu J, Gaiha GD, John SP, et al. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep 2012; 2:807-816.
Li Z, Guo J, Wu Y, Zhou Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res 2013; 41:277-287.
Budhiraja S, Rice AP. Reactivation of latent HIV: do all roads go through PTEFb? Future Virol 2013; 8:649-659.
Derek D, Sloan Alivelu I, Angela T, et al. TLR7 agonist GS-9620 activates HIV- 1 in PBMCS from HIV-infected patients on cART. CROI 2015, Abstract 417 2015.
James B, Whitney. So-Yon Lim, et al. Treatment with a TLR7 agonist induces transient viremia in SIV-infected ART-suppressed monkeys. CROI 2015, Abstract 108 2015.
Spina CA, Anderson J, Archin NM, et al. An in-depth comparison of latent HIV- 1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 2013; 9:e1003834.
Bui JK, Mellors JW, Cillo AR. HIV-1 virion production from single inducible proviruses following T-cell activation ex vivo. J Virol 2015; 90:1673-1676
Laird GM, Bullen CK, Rosenbloom DI, et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 2015; 125:1901-1912
Jones RB, O'Connor R, Mueller S, et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog 2014; 10:e1004287